Stay updated on Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdds a Show glossary option and a new revision label (v3.4.0) to the page, and normalizes capitalization for FEAR Act-related text. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check50 days agoChange DetectedThe Locations section has been expanded to include many new sites across the US, Australia, Canada, and numerous other countries, replacing the previous shorter list. This broadens geographic availability of trial sites.SummaryDifference4%

- Check71 days agoChange DetectedThe page footer revision tag has been updated from Revision: v3.3.1 to Revision: v3.3.2.SummaryDifference0.0%

- Check78 days agoChange DetectedPublications section now clarifies that some items are voluntarily provided and that PubMed-sourced publications are auto-filled; the page also shows revision v3.3.1.SummaryDifference0.5%

- Check85 days agoChange DetectedThe Taiwan location entry was updated to standardize the city name to 'Tainan, Taiwan, 70457'. The old entry 'Tainan City, Taiwan, 70457' was removed and the new listing added.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab ± Lenvatinib in PD-L1+ NSCLC Clinical Trial page.